Cargando…

Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats

To explore how alterations in the phosphodiesterase type 5 (PDE5) signalling pathway and oxidative stress correlate with changes in the expression of relaxation and contraction molecules and erectile dysfunction (ED) in the corpus cavernosum smooth muscle (CCSM) of spontaneously hypertensive rats (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Weixiang, Liu, Jianmin, Liu, Daoquan, Hu, Jundong, Jiang, Ye, Li, Mingzhou, Wang, Qian, Chen, Ping, Zeng, Guang, Xu, Deqiang, Wang, Xinghuan, DiSanto, Michael E., Zhang, Xinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754015/ https://www.ncbi.nlm.nih.gov/pubmed/33118708 http://dx.doi.org/10.1111/jcmm.16045

Ejemplares similares

Identification and functional activity of matrix-remodeling associated 5 (MXRA5) in benign hyperplastic prostate
por: Xiao, He, et al.
Publicado: (2020)

Smoothened inhibition leads to decreased cell proliferation and suppressed tissue fibrosis in the development of benign prostatic hyperplasia
por: Liu, Jianmin, et al.
Publicado: (2021)

The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma
por: Zhou, Yongying, et al.
Publicado: (2021)

Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder
por: He, Weixiang, et al.
Publicado: (2020)

Glucose-regulated protein 78 modulates cell growth, epithelial–mesenchymal transition, and oxidative stress in the hyperplastic prostate
por: Fu, Xun, et al.
Publicado: (2022)

Identification of Seven Aberrantly Methylated and Expressed Genes in Adrenocortical Carcinoma
por: Xiao, He, et al.
Publicado: (2019)

Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 (CXCL13) in Hyperplastic Prostate
por: Liu, Daoquan, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of the Use of Phosphodiesterase Type 5 Inhibitors for Treatment of Erectile Dysfunction following Bilateral Nerve-Sparing Radical Prostatectomy
por: Wang, Xiao, et al.
Publicado: (2014)

Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia
por: Xu, Deqiang, et al.
Publicado: (2019)

Glutathione Peroxidase 3 induced mitochondria-mediated apoptosis via AMPK /ERK1/2 pathway and resisted autophagy-related ferroptosis via AMPK/mTOR pathway in hyperplastic prostate
por: Li, Yan, et al.
Publicado: (2023)

Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-γ and Classic WNT/β-Catenin Pathway
por: Wang, Zhen, et al.
Publicado: (2023)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-β-catenin signaling axis and static & dynamic dual roles
por: Shan, Shidong, et al.
Publicado: (2023)

Identification of Five Genes as a Potential Biomarker for Predicting Progress and Prognosis in Adrenocortical Carcinoma
por: Xiao, He, et al.
Publicado: (2018)

Three novel hub genes and their clinical significance in clear cell renal cell carcinoma
por: Xiao, He, et al.
Publicado: (2019)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Upregulation of Oxytocin Receptor in the Hyperplastic Prostate
por: Li, Zhuo, et al.
Publicado: (2018)

Progesterone reduces erectile dysfunction in sleep-deprived spontaneously hypertensive rats
por: Andersen, Monica L, et al.
Publicado: (2007)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction
por: Wang, Jian, et al.
Publicado: (2021)

Alterations of Phosphodiesterases in Adrenocortical Tumors
por: Hannah-Shmouni, Fady, et al.
Publicado: (2016)

The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis
por: Li, Zhuo, et al.
Publicado: (2016)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Hypertension and erectile dysfunction: The role of endovascular therapy in Asia
por: Wang, Tzung‐Dau, et al.
Publicado: (2020)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction
por: Wang, Rui, et al.
Publicado: (2022)

Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors
por: Tsai, Chia-Chun, et al.
Publicado: (2017)

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension
por: Mergia, Evanthia, et al.
Publicado: (2016)

The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia
por: Liu, Jiang, et al.
Publicado: (2023)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_joavcn710mvrfie1q1m6fmvimq